Nexyra Journal
Structured evidence dossiers on research compounds — clinical trial summaries, mechanism overviews, primary-source citations, and honest evidence-level grading. Each dossier is a reference document, not marketing copy.
All content is for research planning purposes only. Not medical advice. All Nexyra Lab products are for research use and not for human or veterinary use.
Retatrutide — Research Dossier
A structured evidence dossier on Retatrutide (LY3437943), a triple GIP/GLP-1/glucagon receptor agonist. Phase 2 NEJM 2023 data, Phase 3 TRIUMPH toplines (TRIUMPH-1 and TRIUMPH-4), safety profile, regulatory status, and full primary-source references.
Mechanism
Triple agonist
Phase 2 peak result
24.2%
Phase 3 peak result
30.3%
Tesamorelin — Research Dossier
A structured evidence dossier on Tesamorelin (Egrifta), the only FDA-approved GHRH analogue in the Nexyra catalogue. Phase 3 pivotal trial results (15–18% visceral fat reduction), off-label liver research, safety profile, and regulatory status.
Mechanism
GHRH analogue
FDA approval
2010
Visceral fat reduction
15–18%
5-Amino-1MQ — Research Dossier
A structured evidence dossier on 5-Amino-1MQ, a small-molecule NNMT inhibitor (not a peptide). NAD+/sirtuin mechanism, the Kraus and Neelakantan preclinical work, the absence of human trials, and regulatory status.
Class
Small molecule
Target
NNMT inhibition
Downstream
NAD⁺ / sirtuins
AOD-9604 — Research Dossier
A structured evidence dossier on AOD-9604, the lipolytic hGH(176–191) fragment analogue. The Metabolic Pharmaceuticals Phase IIb obesity trial that missed its endpoint, the clean safety dataset, and regulatory status.
Structure
hGH(176–191) + Tyr
Largest trial
Phase IIb
Primary endpoint
Not met (2007)
BPC-157 — Research Dossier
A structured evidence dossier on BPC-157. 35 of 36 studies in a 2025 systematic review are preclinical; zero controlled human trials recorded. Mechanistic pathways, limitations of the rodent literature, and regulatory status.
Studies reviewed
36
Preclinical studies
35
Controlled human trials
0
CJC-1295 — Research Dossier
A structured evidence dossier on CJC-1295. The 2006 Teichman Phase 1/2 trial in healthy adults showed 2–10× sustained GH elevation over 6+ days (DAC form). The widely sold "no-DAC" product is a different molecule. Development did not advance beyond early trials.
Key study
2006
GH increase (DAC)
2–10×
IGF-1 increase (DAC)
1.5–3×
DSIP — Research Dossier
A structured evidence dossier on DSIP (delta sleep-inducing peptide). Discovery, the unresolved mechanism, the thin and inconsistent evidence base, and regulatory status. The most honest grade in the library.
Structure
Nonapeptide (9 aa)
First isolated
1974–1977
Defined receptor
None established
Epitalon — Research Dossier
A structured evidence dossier on Epitalon (epithalon, AEDG). Telomerase/pineal mechanism, the Khavinson rodent longevity and human mortality programme, the single-laboratory caveat, the telomerase-oncogenicity question, and regulatory status.
Sequence
Ala-Glu-Asp-Gly
Origin
Pineal extract
Evidence source
Largely one network
GHK-Cu — Research Dossier
A structured evidence dossier on GHK-Cu (copper tripeptide, glycyl-L-histidyl-L-lysine). Fibroblast and wound-model data, topical cosmetic RCTs, gene-expression modulation, the delivery limitation, and regulatory status.
Discovered
1973
Plasma decline (20→60)
~60%
Injectable human trials
0
GHRP-2 — Research Dossier
A structured evidence dossier on GHRP-2, a synthetic ghrelin-receptor agonist and growth hormone secretagogue. Arvat head-to-head GH potency data, appetite effects, Japanese pharmacology trials, and regulatory status.
Class
GHS-R1a agonist
GH potency
>max-dose GHRH
FDA approval
None
GHRP-6 — Research Dossier
A structured evidence dossier on GHRP-6, the prototype synthetic growth hormone-releasing peptide that templated MK-677. Strong appetite stimulation, cytoprotective research, early human safety data, and regulatory status.
Class
GHS-R1a agonist
Role in drug discovery
Template for MK-677
Appetite effect
Strong (orexigenic)
Gonadorelin — Research Dossier
A structured evidence dossier on Gonadorelin, synthetic gonadotropin-releasing hormone (GnRH). Pituitary mechanism, the pulsatile-versus-continuous distinction, historical approvals, and how it differs from kisspeptin.
Identity
Synthetic GnRH
Site of action
Pituitary
Pulsatile effect
Stimulates LH/FSH
HCG — Research Dossier
A structured evidence dossier on HCG (human chorionic gonadotropin). FDA-approved for fertility and endocrine indications. The weight-loss claim is unsupported: a 24-study meta-analysis found no evidence of benefit; the FDA label states it is not effective for obesity. OTC HCG weight-loss products were declared fraudulent in 2011.
FDA status
Approved
Weight-loss evidence
None
OTC HCG products
Banned 2011
Hexarelin — Research Dossier
A structured evidence dossier on Hexarelin, the most potent traditional growth hormone-releasing peptide. GH potency data, cardiac CD36 research, desensitisation and cortisol/prolactin caveats, and regulatory status.
Class
GHS-R1a agonist
GH potency
Highest of traditional GHRPs
Secondary target
Cardiac CD36
HGH — Research Dossier
A structured evidence dossier on recombinant human growth hormone (somatropin). FDA-approved for defined deficiency states; controlled trials in healthy elderly show modest body-composition change with significant adverse effects — risks outweigh benefits.
Structure
191 aa
FDA status
Approved
Anti-ageing use
Not approved
Ipamorelin — Research Dossier
A structured evidence dossier on Ipamorelin. Two human PK/PD studies; one discontinued Phase 2 (postoperative ileus). Selectively stimulates GH without raising cortisol, prolactin, or ACTH — a pharmacological distinction established mainly in preclinical models. No approvals.
First described
1998
Human PK/PD studies
2
Phase 2 trials
1
Kisspeptin-10 — Research Dossier
A structured evidence dossier on Kisspeptin-10. KISS1R/HPG-axis mechanism, the Imperial College human studies, the kisspeptin-10 vs kisspeptin-54 distinction, desensitisation, and regulatory status.
Receptor
KISS1R (GPR54)
Position in HPG axis
Upstream of GnRH
Clinical lead form
Kisspeptin-54
KPV — Research Dossier
A structured evidence dossier on KPV (Lys-Pro-Val), the anti-inflammatory C-terminal tripeptide of alpha-MSH. NF-κB/PepT1 mechanism, colitis and dermatitis models, the absence of human trials, and regulatory status.
Sequence
Lys-Pro-Val
Mechanism
NF-κB inhibition
Tanning/appetite effects
None
MK-677 — Research Dossier
A structured evidence dossier on MK-677 (ibutamoren), an orally active non-peptide ghrelin-receptor agonist. The Nass 2-year RCT, IGF-1 elevation, insulin-resistance signal, the negative Alzheimer trial, and regulatory status.
Class
Oral non-peptide GHS
Longest RCT
2 years
Half-life
~24 h
Mod GRF (1-29) — Research Dossier
A structured evidence dossier on Mod GRF (1-29) — the molecule sold as "CJC-1295 no-DAC". Naming clarification versus DAC CJC-1295, the absence of direct human trials, and regulatory status.
Identity
CJC-1295 no-DAC
Basis
GHRH(1-29)
DAC present?
No
MOTS-c — Research Dossier
A structured evidence dossier on MOTS-c, a mitochondrial-derived peptide. AMPK mechanism, the Lee 2015 founding work, exercise-mimetic rodent data, the mixed human association data, and regulatory status.
Structure
16-aa, mtDNA
Primary pathway
AMPK
Human evidence
Early / mixed
NAD⁺ — Research Dossier
A structured evidence dossier on NAD⁺. Age-related decline is well documented. Most human RCT evidence tests oral precursors (NR/NMN) and surrogate endpoints — NAD⁺ levels, not hard clinical outcomes. Direct evidence for injectable NAD⁺ is limited.
Age-related decline
Multi-tissue
Precursor effect (NR/NMN)
~2×
Human endpoints
Surrogate-led
Selank — Research Dossier
A structured evidence dossier on Selank, a synthetic tuftsin analogue. Anxiolytic mechanism, the Russian GAD trial versus medazepam, BDNF and immunomodulatory data, the Western-replication gap, and regulatory status.
Sequence
Thr-Lys-Pro-Arg-Pro-Gly-Pro
GAD comparator (n)
62
Large Western RCTs
0
Semax — Research Dossier
A structured evidence dossier on Semax. Genuine clinical registration in Russia, ischaemic-stroke trial data, preclinical BDNF and monoamine findings, the Western replication gap, and regulatory status outside Russia.
Registered in Russia
1994
Amino acid sequence
Heptapeptide
Large Western RCTs
0
Sermorelin — Research Dossier
A structured evidence dossier on Sermorelin (GHRH 1-29, Geref). FDA approval and withdrawal history, pediatric GHD trial data, the somatostatin feedback safety feature, WADA status, and regulatory position.
Structure
GHRH(1-29)
FDA approval (Geref)
1997
Withdrawn (commercial)
2008
TB-500 — Research Dossier
A structured evidence dossier on TB-500 (thymosin beta-4). Phase 2–3 human trials exist in ophthalmic and dermal indications; zero completed trials for systemic musculoskeletal use. Evidence base, naming distinction from thymosin alpha-1, and regulatory status.
First isolated
1960s
Human trial stage
Phase 2–3
Musculoskeletal trials
0
Thymosin Alpha-1 — Research Dossier
A structured evidence dossier on Thymosin Alpha-1 (thymalfasin, Zadaxin). TLR-mediated immune mechanism, hepatitis B/C and sepsis trial data, approval in 35+ countries, the absence of US approval, and regulatory status.
Structure
28-amino-acid
Approved (ex-US)
35+ countries
Human subjects
11,000+
About this library
Dossiers are published when sufficient primary-source evidence exists to compile a substantive, well-referenced summary. Each entry is reviewed periodically as new trial data becomes available. Evidence-level grading reflects the current highest-quality published evidence; it is not an endorsement of any therapeutic use.
